Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 8551–8600 of 34746
David Henshall, Kent Mathy, Alison Dean, Sharon Rowlands, Simon Paris, David Benjamin, Richard D’Amore and Rohit Ghai, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
David Henshall, Kent Mathy, Alison Dean, Sharon Rowlands, Simon Paris, David Benjamin, Richard D’Amore and Rohit Ghai, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
David Henshall, Kent Mathy, Alison Dean, Sharon Rowlands, Simon Paris, David Benjamin, Richard D’Amore and Rohit Ghai, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
David Henshall, Kent Mathy, Alison Dean, Sharon Rowlands, Simon Paris, David Benjamin, Richard D’Amore and Rohit Ghai, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Following the Effective Time, David Wagner shall remain a director of the Company, and David Rockvam and Noah Webster were appointed directors of the Company.
the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed John P. Furey to the Board as a Class II director, which appointment became effective on July 2, 2024.
Effective July 1, 2024, the Registrant’s Board of Directors increased the size of the Board of Directors by one, and elected Raymond J. Vanaria, age 65, to serve as a director of the Registrant in the class whose term expires in 2026.
the Board and Ms. Kast, a director of the Registrant, agreed that she would not stand for re-election as a director of the Registrant at its 2024 annual meeting of shareholders.
Peter Beitsch, MD, and Matthew Schwartz, MD joined the Board, effective June 26, 2024.
Peter Beitsch, MD, and Matthew Schwartz, MD joined the Board, effective June 26, 2024.
On June 30, 2024, William Horne resigned as member of the Board of Directors of Innoveren Scientific, Inc. (the “Company”).
On June 28, 2024, the Board of Directors (the “Board”) of Caesars Entertainment, Inc. (the “Company”) increased the size of the Board from ten directors to eleven directors and subsequently elected Rodney Williams to fill the vacancy, effective July 1, 2024, subject to customary regulatory approvals and requirements pending licensure.
On July 1, 2024, the Board of Directors (the “Board”) of Franklin Electric Co., Inc. (the “Company”) appointed Mr. Joseph Ruzynski as a director, effective immediately.
elected Cyrus Taraporevala to serve as a member of the Company’s Board, effective immediately.
On June 30, 2024, John W. Gildea and Mitchell I. Quain resigned from the Board of Directors (the “Board”) of Star Equity Holdings, Inc. (the “Company”) and all committees of the Board effective as of such date.
On July 1, 2024, the Board elected Jennifer Palmer, Todd Fruhbeis and Louis Parks to the Board, replacing Mitchell I. Quain and John W. Gildea.
On July 1, 2024, the Board elected Jennifer Palmer, Todd Fruhbeis and Louis Parks to the Board, replacing Mitchell I. Quain and John W. Gildea.
On June 30, 2024, John W. Gildea and Mitchell I. Quain resigned from the Board of Directors (the “Board”) of Star Equity Holdings, Inc. (the “Company”) and all committees of the Board effective as of such date.
On July 1, 2024, the Board elected Jennifer Palmer, Todd Fruhbeis and Louis Parks to the Board, replacing Mitchell I. Quain and John W. Gildea.
On June 28, 2024, April Chapman submitted correspondence stating her desire to resign her board position due to other commitments.
On June 28, 2024, the Board of Directors (the “Board”) of Superior Industries International, Inc. (the “Company” or “Superior”) appointed Michael Guo to serve as a member of the Board until his successor is elected and qualified or until his earlier resignation or removal, effective July 1, 2024.
On June 28, 2024, the Board of Directors (the “Board”) of Performance Food Group Company (the “Company”) appointed Danielle M. Brown to the Board, effective immediately.
On June 26, 2024, Ted Davis, a member of the Board of Directors of Alpha Teknova, Inc. (the “Company”), notified the Company of his intention to retire from the Company’s Board of Directors (the “Board”).
On June 30, 2024, Tim Kutzkey, Ph.D. notified Surrozen, Inc. of his resignation as a member of our board of directors and from all committees of the board of directors on which he served, effective as of June 30, 2024.
On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.
On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.
On June 28, 2024, pursuant to the 22NW Cooperation Agreement, the Board, upon the recommendation of the Nominating Committee, appointed Paul H. Johnson, Humberto C. Antunes, and Matthew Korenberg as directors, effective immediately following the conclusion of the 2023 Annual Meeting.
Wendy Becker informed Logitech of her decision not to stand for re-election to the Board next year at the Company’s 2025 AGM (assuming Ms. Becker’s re-election at the 2024 AGM).
Patrick Aebischer will not stand for re-election to the board of directors (the “Board”) at the Company’s 2024 Annual General Meeting (the “AGM”), when his current term ends, due to the Company's limits on board service, and not due to any disagreement relating to Logitech’s operations, policies or practices.
On June 26, 2024, each of Regina Hodits, Ph.D. and Björn Odlander, M.D., Ph.D. notified Carisma Therapeutics Inc. (the “Company”) of their respective decisions to resign from the Company’s board of directors, effective June 30, 2024.
On June 26, 2024, each of Regina Hodits, Ph.D. and Björn Odlander, M.D., Ph.D. notified Carisma Therapeutics Inc. (the “Company”) of their respective decisions to resign from the Company’s board of directors, effective June 30, 2024.
On June 26, 2024, the board of directors elected Marella Thorell and David Scadden, M.D. as directors of the Company, effective June 30, 2024.
On June 26, 2024, the board of directors elected Marella Thorell and David Scadden, M.D. as directors of the Company, effective June 30, 2024.
The eight FNCB Continuing Directors designated by FNCB pursuant to the Merger Agreement and the Peoples bylaw amendment, each of whom was serving as a member of the board of directors of FNCB immediately prior to the Effective Time, and was appointed as a member of the Board effective as of the Effective Time, are as follows: Louis A. DeNaples, Sr., William G. Bracey, Joseph Coccia, William P. Conaboy, Joseph L. DeNaples, Keith W. Eckel, Kathleen M. Lambert, and Thomas J. Melone.
The eight FNCB Continuing Directors designated by FNCB pursuant to the Merger Agreement and the Peoples bylaw amendment, each of whom was serving as a member of the board of directors of FNCB immediately prior to the Effective Time, and was appointed as a member of the Board effective as of the Effective Time, are as follows: Louis A. DeNaples, Sr., William G. Bracey, Joseph Coccia, William P. Conaboy, Joseph L. DeNaples, Keith W. Eckel, Kathleen M. Lambert, and Thomas J. Melone.
Mr. DeNaples, Sr., the chairman of the FNCB board of directors immediately prior to the Effective Time, was appointed as Vice Chairman of the Board.
The eight FNCB Continuing Directors designated by FNCB pursuant to the Merger Agreement and the Peoples bylaw amendment, each of whom was serving as a member of the board of directors of FNCB immediately prior to the Effective Time, and was appointed as a member of the Board effective as of the Effective Time, are as follows: Louis A. DeNaples, Sr., William G. Bracey, Joseph Coccia, William P. Conaboy, Joseph L. DeNaples, Keith W. Eckel, Kathleen M. Lambert, and Thomas J. Melone.
The eight FNCB Continuing Directors designated by FNCB pursuant to the Merger Agreement and the Peoples bylaw amendment, each of whom was serving as a member of the board of directors of FNCB immediately prior to the Effective Time, and was appointed as a member of the Board effective as of the Effective Time, are as follows: Louis A. DeNaples, Sr., William G. Bracey, Joseph Coccia, William P. Conaboy, Joseph L. DeNaples, Keith W. Eckel, Kathleen M. Lambert, and Thomas J. Melone.
The eight FNCB Continuing Directors designated by FNCB pursuant to the Merger Agreement and the Peoples bylaw amendment, each of whom was serving as a member of the board of directors of FNCB immediately prior to the Effective Time, and was appointed as a member of the Board effective as of the Effective Time, are as follows: Louis A. DeNaples, Sr., William G. Bracey, Joseph Coccia, William P. Conaboy, Joseph L. DeNaples, Keith W. Eckel, Kathleen M. Lambert, and Thomas J. Melone.
The eight FNCB Continuing Directors designated by FNCB pursuant to the Merger Agreement and the Peoples bylaw amendment, each of whom was serving as a member of the board of directors of FNCB immediately prior to the Effective Time, and was appointed as a member of the Board effective as of the Effective Time, are as follows: Louis A. DeNaples, Sr., William G. Bracey, Joseph Coccia, William P. Conaboy, Joseph L. DeNaples, Keith W. Eckel, Kathleen M. Lambert, and Thomas J. Melone.
The eight FNCB Continuing Directors designated by FNCB pursuant to the Merger Agreement and the Peoples bylaw amendment, each of whom was serving as a member of the board of directors of FNCB immediately prior to the Effective Time, and was appointed as a member of the Board effective as of the Effective Time, are as follows: Louis A. DeNaples, Sr., William G. Bracey, Joseph Coccia, William P. Conaboy, Joseph L. DeNaples, Keith W. Eckel, Kathleen M. Lambert, and Thomas J. Melone.
The eight FNCB Continuing Directors designated by FNCB pursuant to the Merger Agreement and the Peoples bylaw amendment, each of whom was serving as a member of the board of directors of FNCB immediately prior to the Effective Time, and was appointed as a member of the Board effective as of the Effective Time, are as follows: Louis A. DeNaples, Sr., William G. Bracey, Joseph Coccia, William P. Conaboy, Joseph L. DeNaples, Keith W. Eckel, Kathleen M. Lambert, and Thomas J. Melone.
The Board also appointed Kate Sampson as a non-employee director of the Company
On July 1, 2024, in connection with the closing of the Private Placement and in accordance with the Purchase Agreement, Board unanimously voted to increase the size of the Board from six to seven directors, and to appoint Mr. Daniel M. Friedberg to fill the newly created Board position, to serve until his successor shall have been duly elected and qualified or until his earlier death, resignation or removal.
the six directors designated by Codorus Valley pursuant to the Merger Agreement, each of whom previously served as a member of the board of directors of Codorus Valley and PeoplesBank, and were appointed by the Orrstown Board and the Orrstown Bank Board, in each case effective as of the Effective Time, are as follows: Sarah M. Brown, Brian D. Brunner, Scott V. Fainor, John W. Giambalvo, Craig L. Kauffman and J. Rodney Messick.
the six directors designated by Codorus Valley pursuant to the Merger Agreement, each of whom previously served as a member of the board of directors of Codorus Valley and PeoplesBank, and were appointed by the Orrstown Board and the Orrstown Bank Board, in each case effective as of the Effective Time, are as follows: Sarah M. Brown, Brian D. Brunner, Scott V. Fainor, John W. Giambalvo, Craig L. Kauffman and J. Rodney Messick.
the six directors designated by Codorus Valley pursuant to the Merger Agreement, each of whom previously served as a member of the board of directors of Codorus Valley and PeoplesBank, and were appointed by the Orrstown Board and the Orrstown Bank Board, in each case effective as of the Effective Time, are as follows: Sarah M. Brown, Brian D. Brunner, Scott V. Fainor, John W. Giambalvo, Craig L. Kauffman and J. Rodney Messick.
the six directors designated by Codorus Valley pursuant to the Merger Agreement, each of whom previously served as a member of the board of directors of Codorus Valley and PeoplesBank, and were appointed by the Orrstown Board and the Orrstown Bank Board, in each case effective as of the Effective Time, are as follows: Sarah M. Brown, Brian D. Brunner, Scott V. Fainor, John W. Giambalvo, Craig L. Kauffman and J. Rodney Messick.
the six directors designated by Codorus Valley pursuant to the Merger Agreement, each of whom previously served as a member of the board of directors of Codorus Valley and PeoplesBank, and were appointed by the Orrstown Board and the Orrstown Bank Board, in each case effective as of the Effective Time, are as follows: Sarah M. Brown, Brian D. Brunner, Scott V. Fainor, John W. Giambalvo, Craig L. Kauffman and J. Rodney Messick.
the six directors designated by Codorus Valley pursuant to the Merger Agreement, each of whom previously served as a member of the board of directors of Codorus Valley and PeoplesBank, and were appointed by the Orrstown Board and the Orrstown Bank Board, in each case effective as of the Effective Time, are as follows: Sarah M. Brown, Brian D. Brunner, Scott V. Fainor, John W. Giambalvo, Craig L. Kauffman and J. Rodney Messick.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.